Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 15 posts of 128 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …

News
celgene_1_02

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

November 15, 2016
Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …

News
ibm_web

Celgene partners with IBM for new pharmacovigilance platform

November 2, 2016
Research and Development, Sales and Marketing Celgene, Watson, ibm

IBM is set to join forces with Celgene to develop a new drug safety evaluation platform, it has emerged. Running …

News
celgene_1_02

Celgene’s Otezla approved by NICE for chronic plaque psoriasis

October 20, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla

NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …

News
celgene_1_02

Celgene trial displays promising results for Crohn’s disease alternative treatment

October 17, 2016
Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial

Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …

News

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016
Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

News
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016
Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News
celgene_1_02

Celgene and Agios to file FDA application for “first-in-class” cancer drug

September 8, 2016
Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios

According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …

News
celgene_1_02

Celgene’s Otezla approved for NHS use

August 3, 2016
Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …

News
celgene_1_02

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016
Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …

News
celgene_1_02

Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics

July 19, 2016
Research and Development, Sales and Marketing Celgene, jounce

Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …

News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016
Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 

News
logo

AstraZeneca mulling a $10-billion bid for Medivation – report

July 12, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition

Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …

News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024